Could a drug make stem cell transplants safer and more effective?
NCT ID NCT02356159
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 23 times
Summary
This study tested a drug called palifermin in 34 adults with blood cancers who received stem cell transplants from unrelated donors. The goal was to see if palifermin could reduce severe chronic graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. Participants received palifermin before transplant and were monitored for safety and outcomes for up to 5 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
-
National Marrow Donor Program
Minneapolis, Minnesota, 55401, United States
Conditions
Explore the condition pages connected to this study.